# A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

Source: https://onco.cc/trials/nct04485949/  
OnCo record `nct04485949` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Temozolomide in glioma & glioblastoma, run by Imvax, active and no longer recruiting.

## Summary

A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma is a phase 2 interventional study registered as NCT04485949 by Imvax, with 99 participants enrolled, started 2023-03-20 and due to reach its primary completion in 2027-01. Interventions recorded: IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy and SOC: Temozolomide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04485949
- Phase: 2
- Setting: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
- Sponsor: Imvax
- Enrolled: 99

## Sources

- ClinicalTrials.gov NCT04485949: https://clinicaltrials.gov/study/NCT04485949

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)

---
JSON: https://onco.cc/api/v1/entities/nct04485949.json